Inicure
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at Inicure
Sara Malcus
Chair of the Board of Directors
About Inicure
Inicure AB is a Swedish biotech company developing a new class of immune-activating therapies to combat antibiotic-resistant infections. Our innovative small-molecule FPR1 agonists boost the body’s own immune response—offering a resistance-free alternative to traditional antibiotics. Founded in 2024 as a spin-off from Pronoxis AB and GU Ventures, Inicure is advancing promising preclinical compounds with strong efficacy and safety profiles, supported by leading academic and industry partners.
$
Inicure revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Funding Data
Inicure has never raised funding before.
Canada
United States
Australia
United Kingdom
BrazilFrequently asked questions
Inicure is located in XX.
Inicure has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
